Swan F, Velasquez W S, Tucker S, Redman J R, Rodriguez M A, McLaughlin P, Hagemeister F B, Cabanillas F
Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
J Clin Oncol. 1989 Oct;7(10):1518-27. doi: 10.1200/JCO.1989.7.10.1518.
We report results of our investigation of prognostic factors for patients with large-cell lymphoma who were entered on the same treatment protocol and who had known pretreatment serum beta 2-microglobulin (beta 2M) and lactate dehydrogenase (LDH) levels. beta 2M and LDH levels were the most significant and independent variables for predicting time to treatment failure (TTF) and survival. The serum level of beta 2M correlated with tumor burden. These two serum markers defined three significantly different prognostic groups. All 27 patients in the low-risk group remain alive and in remission; in contrast, 22 of the 27 patients (81%) in the high-risk group have failed treatment, and only seven (26%) remain alive. In comparison with the Ann Arbor staging system, serum levels of beta 2M and LDH may provide a more precise system for defining risk groups and thereby allow a more rational approach to the development and analysis of treatment strategies.
我们报告了对大细胞淋巴瘤患者预后因素的调查结果，这些患者采用相同的治疗方案，且已知治疗前血清β2-微球蛋白（β2M）和乳酸脱氢酶（LDH）水平。β2M和LDH水平是预测治疗失败时间（TTF）和生存率的最显著且独立的变量。β2M血清水平与肿瘤负荷相关。这两种血清标志物界定了三个显著不同的预后组。低风险组的所有27名患者均存活且处于缓解期；相比之下，高风险组的27名患者中有22名（81%）治疗失败，仅7名（26%）存活。与Ann Arbor分期系统相比，β2M和LDH的血清水平可能为界定风险组提供更精确的系统，从而为治疗策略的制定和分析提供更合理的方法。
